Mevidalen
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Mevidalen
- Molecular weight
- 450.41
- Structure (SMILES)
- C[C@H]1c2cccc(CCC(C)(C)O)c2C[C@H](CO)N1C(=O)Cc1c(Cl)cccc1Cl
- ly 3154207
- LY-3154207
- ly3154207
- Ly3154207
- LY3154207
- LY3154207 Capsule
- LY3154207 Tablet
- mevidalen
- Mevidalen
- mevidalen [INN]
- MEVIDALEN [USAN]
- mevidalen inn
- mevidalen usan
- CAS registry numbers
- 1638667-79-4
- ChEMBL ID
- CHEMBL3421729
- InChIKey
- XHCSBQBBGNQINS-DOTOQJQBSA-N
- PubChem compound IDs
- 86290953
- FDA ingredient codes (UNII)
- 4A3702A96F
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- mevidalen
- Type
- Synthetic organic
- Drug name stem
- -dalen
- Mechanism
- Dopamine D1 receptor positive allosteric modulator
- Action type
- POSITIVE_ALLOSTERIC_MODULATOR
- Target
- D(1A) dopamine receptor
- Protein identifier
- P21728
- Action
- Positive
- Action type
- POSITIVE
- Target
- D1 receptor
- Gene symbol
- DRD1
- Protein identifier
- P21728
- Median affinity
- 8.64
- Affinity units
- pEC50
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Dopamine D1 receptor positive allosteric modulator
- Action type
- POSITIVE ALLOSTERIC MODULATOR
- Target
- D(1A) dopamine receptor
- Condition
- Lewy Body Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0006792
- Subject identifier
- D020961
- Condition
- Alzheimer Disease
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
- Condition
- Parkinson Disease
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005180
- Subject identifier
- D010300
- Condition identifier
- EFO_0006792
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001627
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005180
- Highest recorded phase
- 2
- NCT02562768
- NCT03305809
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 2
- Polar surface area
- 60.77
- Calculated partition coefficient (ALogP)
- 4.75
- Calculated partition coefficient (XLogP)
- 4.4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 30
- Molecular formula
- C24H29Cl2NO3
- Monoisotopic mass
- 449.1524492
- Natural product
- No
- Recorded assays
- 111
- Active assays
- 10
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (8)
- A Drug Interaction Study of LY3154207 in Healthy Participants
- A Study of LY3154207 in Healthy Participants
- A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
- A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
- A Study of LY3154207 on Sleep in Healthy Male Participants
- A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
- A Study to Evaluate LY3154207 on the Brain of Healthy Participants
- Study of LY3154207 in Healthy Participants
In development for (3)
- Alzheimer disease Phase 1
- Lewy body dementia Phase 2
- Parkinson disease Phase 1
Targets (1)
- DRD1 Dopamine D1 receptor positive allosteric modulator